Emerging studies suggest this peptide, a dual stimulator targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a notable step forward for body management . Early clinical trials have shown considerable losses in abdominal fat , possibly exceeding other body composition treatments. Nevertheless , further assessment